Skip to content
AnalystLens

Charles River Laboratories International Annual Report, Year Ended Dec 28, 2002

Filing Date
Filed March 20, 2003
Period End
December 28, 2002
Security
CRL
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Apr ’18Apr ’18
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jan ’26Jan ’26

Summary

Summary of the 10-K filed March 20, 2003. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. reported net sales of $554.6 milliona for fiscal 2002, up 19.1% from $465.6 million in 2001, with operating income of $122.3 million, a 35.4% increase over 2001.

Net income was $50.1 millionb, compared with $35.4 million in 2001. Income before extraordinary item was $68.4 million, or $1.42 per diluted share, and the extraordinary loss was $18.2 million, net of tax, mainly from debt repayments. The company operates in two segments: Research Models, which contributed 40.3% of 2002 net sales and was the most profitable at a 31.7% operating margin, and Biomedical Products and Services, which contributed 59.7% of net sales.

Cash from operations rose to $133.7 millionc in 2002 from $71.3 million in 2001. The company refinanced its debt during the year by issuing $185.0 million of 3.5% senior convertible debentures due 2022 and using the proceeds to retire the 13.5% senior subordinated notes. It also repaid its senior secured term loans and terminated its revolving credit facility, and it is negotiating a $100-125 million line of credit expected to close in March 2003.

Total debt was $195.8 milliond at year end, and shareholders' equity was $357.4 million. The filing highlights risks including exposure to government and pharmaceutical research spending, customer contracts that can be terminated on little or no notice, and foreign currency exposure, since the company does not hedge.

It also notes a $78.5 million deferred tax asset tied to a 1999 recapitalization election that the IRS could challenge. In 2002, development services faced weaker performance in two smaller units, and management expects development services performance to improve by the end of 2003.

Key Highlights

  1. Net sales rose 19.1% to $554.6 million in 2002, and operating income rose 35.4% to $122.3 million.
  2. Net income was $50.1 million in 2002, compared with $35.4 million in 2001, after an $18.2 million extraordinary loss on debt repayment.
  3. Diluted EPS before extraordinary item was $1.42, up 54.3% from 2001, and the filing notes SFAS No. 142 reduced EPS by $0.09 per diluted share.
  4. Research Models segment operating margin reached 31.7% of net sales, compared with 25.8% in 2001, and the segment accounted for 40.3% of net sales.
  5. Cash flow from operations was $133.7 million in 2002, up from $71.3 million in 2001, and cash and equivalents ended the year at $122.5 million.
  6. The company issued $185.0 million of 3.5% senior convertible debentures due 2022 and retired its 13.5% senior subordinated notes and senior secured term loans.
  7. A $78.5 million deferred tax asset from the 1999 recapitalization could be written off if the IRS challenges the Section 338(h)(10) election.

Frequently Asked Questions

  1. How did Charles River perform financially in 2002?

    Net sales were $554.6 million, up 19.1% from $465.6 million in 2001. Operating income was $122.3 million, and net income was $50.1 million after an extraordinary loss of $18.2 million net of tax. Income before the extraordinary item was $68.4 million.

  2. Which business segment drove the results?

    Biomedical Products and Services made up 59.7% of 2002 net sales, with sales of $330.9 million, up 23.4%, helped by the BioLabs and Springborn acquisitions. Research Models made up 40.3% of net sales, with sales of $223.7 million, up 13.3%, and a 31.7% operating margin. The filing states that the development services business was weaker in late 2002.

  3. How did the company change its debt structure in 2002?

    The company issued $185.0 million of 3.5% senior convertible debentures maturing in 2022 and used proceeds to retire all 13.5% senior subordinated notes through a tender offer. It also repaid all senior secured term loans and terminated its revolving credit facility. Total debt was $195.8 million at year end, compared with $156.8 million a year earlier.

  4. What are the main risks identified in the filing?

    Key risks include reduced or delayed government and pharmaceutical R&D funding, customer contracts terminable on little or no notice, international operations and currency exposure with no hedging, acquisition integration, animal-population contamination, and competition. The filing also flags a possible IRS challenge to tax benefits that could require a write-off of the deferred tax asset.

  5. What did the company say about its outlook?

    The company said it expects research and development spending to continue in 2003 at least consistent with the increases of the past two years, and expects demand for research models to remain strong through 2003. It also said the trend toward late-stage discovery is expected to reduce spending on development services through at least the first three quarters of 2003, and it expects development services operating performance to improve by the end of 2003.